Edition:
United States

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

0.68USD
23 Apr 2018
Change (% chg)

$-0.03 (-4.10%)
Prev Close
$0.71
Open
$0.69
Day's High
$0.70
Day's Low
$0.65
Volume
52,265
Avg. Vol
47,081
52-wk High
$8.00
52-wk Low
$0.65

Chart for

About

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies,... (more)

Overall

Beta: 2.45
Market Cap(Mil.): $15.77
Shares Outstanding(Mil.): 22.27
Dividend: 29.10
Yield (%): --

Financials

  ALT.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -3.63 -- --
ROI: -98.35 -0.74 13.19
ROE: -140.31 -2.80 15.00

BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine

* ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION

Mar 27 2018

BRIEF-Altimmune Announces Pre-Clinical Data From Its Sparvax-L Anthrax Vaccine Program

* ALTIMMUNE ANNOUNCES PRE-CLINICAL DATA FROM ITS SPARVAX-L ANTHRAX VACCINE PROGRAM

Mar 12 2018

BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune

* HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING Source text for Eikon: [http://bit.ly/2nwUAiB] Further company coverage:

Feb 02 2018

BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.

* ALTIMMUNE ANNOUNCES NOTICE OF ALLOWANCE ON PATENT COVERING USE OF NASOSHIELD IN THE U.S. Source text for Eikon: Further company coverage:

Jan 23 2018

BRIEF-Altimmune Elects Mitchel Sayare As Chairman Of Its Board

* ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS

Jan 03 2018

BRIEF-Altimmune reports Q3 loss per share $2.05

* Altimmune announces third quarter 2017 financial results and provides corporate update

Nov 09 2017

Competitors

Earnings vs. Estimates